The formulation combines components that work synergistically, from promoting the fermentation of prebiotic fibers for short-chain fatty acid production to directly supporting intestinal L-cells for GLP-1 release
Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, et al
Injection Site Reactions In clinical trials in adults for weight reduction, 1.4% of WEGOVY-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation)
Most clinical trials on the efficacy of GLP-1 RAs found a reduced systolic BP, and this beneficial effect was somewhat more apparent in studies of liraglutide and exenatide (Table 2)